News & Videos - VALEANT PHARMACEUTICALS INTERNATIONAL

Les cabinets d'avocats Faguy & Co. Inc., Siskinds LLP, Siskinds Desmeules, Koskie Minsky LLP, Strosberg Sasso Sutts LLP, Rochon Genova LLP, Morganti & Co. P.C, et Investigation Counsel P.C. annoncent que le 16 novembre 2020, la Cour supérieure du Québec a approuvé une entente de règlement (« règlement ») entre les demandeurs et Valeant Pharmaceuticals International Inc. (maintenant Bausch Health Companies Inc.) (« Valeant ») au nom de tous les défendeurs restant dans le dossier no...

VRX Investor Alert: Kyros Law is Filing Legal Claims on Behalf of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) Investors PR Newswire BOSTON, March 30, 2020 BOSTON , March 30, 2020 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals (NYSE: VRX), now Bausch Health Companies (NYSE: BHC) that it is filing legal claims against the company on behalf of investors. The company has recently agreed to settle a shareholder lawsuit filed against...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX PR Newswire NEW YORK, June 19, 2018 NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valeant Pharmaceuticals International, Inc. - VRX PR Newswire NEW YORK, June 19, 2018 NEW YORK , June 19, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 9980. The investigation...

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Valeant Pharmaceuticals International, Inc. (VRX) PR Newswire NEW YORK, June 19, 2018 NEW YORK , June 19, 2018 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Valeant Pharmaceuticals International, Inc. ("Valeant" or the "Company") (NYSE: VRX). Such investors are encouraged to obtain additional information and assist the...

FDA Issues Complete Response Letter For DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion PR Newswire LAVAL, Quebec, June 18, 2018 LAVAL, Quebec , June 18, 2018 /PRNewswire/ -- Ortho Dermatologics, a division of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company's New Drug Application (NDA) for DUOBRII ™ 1 (halobetasol propionate and...

TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Wednesday's trending market topics from the floor of the New York ......

Valeant Announces Closing Of Amended And Restated Credit Agreement Transaction And Senior Notes Offering, As Well As Redemption Of Existing Senior Notes PR Newswire LAVAL, Quebec, June 1, 2018 LAVAL, Quebec , June 1, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it has entered into a Fourth Amended & Restated Credit and Guaranty Agreement (the "New Credit Agreement") effectuating a full refinancing of its...

Salix To Highlight New Clinical Data During Digestive Disease Week PR Newswire BRIDGEWATER, N.J., May 31, 2018 Oral Presentation and Eight Posters to be Featured BRIDGEWATER, N.J. , May 31, 2018 /PRNewswire/ -- Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal disorders and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), will present new scientific data, including one podium...

Valeant Announces Pricing Of Private Offering Of Notes PR Newswire LAVAL, Quebec, May 17, 2018 LAVAL, Quebec , May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has priced its previously announced offering of $750,000,000 aggregate principal amount of 8.50% unsecured senior notes due 2027 (the "Notes"). The...

Valeant Announces Launch Of Private Offering Of Notes And Upsize Of Term Loans PR Newswire LAVAL, Quebec, May 17, 2018 LAVAL, Quebec , May 17, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that Valeant Pharmaceuticals International (the "Issuer"), the Company's wholly owned indirect subsidiary, has launched an offering of $750,000,000 aggregate principal amount of unsecured senior notes due 2027 (the "Notes"). As...

Valeant to Participate at the 2018 Barclays High Yield Bond and Syndicated Loan Conference PR Newswire LAVAL, Quebec, May 15, 2018 LAVAL, Quebec , May 15, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen , executive vice president, Finance and chief financial officer, and Arthur J. Shannon , senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Barclays High...

VRX Investor Alert: Kyros Law Announces that it is Filing Legal Claims on Behalf of Valeant Pharmaceuticals Intl (NYSE: VRX) Investors PR Newswire BOSTON, May 15, 2018 BOSTON , May 15, 2018 /PRNewswire/ -- Kyros Law Offices is alerting investors of Valeant Pharmaceuticals Intl (NYSE:VRX) that it is filling legal claims against the company for possible securities fraud violations committed by Valeant Pharmaceuticals Intl (NYSE:VRX). Kyros Law has recently signed numerous investors that have lost...

Valeant To Participate At 2018 Bank Of America Merrill Lynch Healthcare Conference PR Newswire LAVAL, Quebec, May 10, 2018 LAVAL, Quebec , May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Joseph C. Papa , chairman and chief executive officer, and Arthur J. Shannon , senior vice president and head of Investor Relations and Communications, are scheduled to participate at the Bank of America Merrill Lynch Healthcare Conference...

Valeant To Seek Refinancing of its Existing Credit Agreement PR Newswire LAVAL, Quebec, May 10, 2018 LAVAL, Quebec , May 10, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company") today announced that it is seeking to amend and restate its existing credit agreement (the "Credit Agreement") and borrow $3.815 billion of new Term B loans (the "New Term B Loans") under the Credit Agreement. The amendment and restatement is expected to have the...

Valeant might be distancing itself from its past with a new name and ticker symbol, but is that enough to change its image? Jim Cramer sits down with CEO ......

Valeant Will Become Bausch Health Companies Inc. PR Newswire LAVAL, Quebec, May 8, 2018 Bausch Health Companies Inc. Accurately Represents the Breadth of the Company Today and Reflects the Innovative Legacy of the Bausch Name Name Change Will be Effective in July 2018 LAVAL, Quebec , May 8, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant" or the "Company" or "we") today announced that the Company will change its name to Bausch Health Companies Inc.,...

Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance PR Newswire LAVAL, Quebec, May 8, 2018 LAVAL, Quebec , May 8, 2018 /PRNewswire/ -- Outperformed Expectations in the First Quarter of 2018 Revenues of $1.995 Billion GAAP Net Loss of $2.693 Billion GAAP Cash Flow from Operations of $438 Million Adjusted EBITDA (non-GAAP) 1 of $832 Million Delivered Overall Organic Revenue Growth 2 for the First Time since 2015, Driven by Branded Rx and Bausch +...

Salix Receives FDA Approval For PLENVU®, Next Generation 1-Liter Bowel Cleansing Preparation For Colonoscopies PR Newswire BRIDGEWATER, N.J., May 7, 2018 BRIDGEWATER, N.J. , May 7, 2018 /PRNewswire/ -- Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX), and its partner Norgine...

Valeant To Participate At Goldman Sachs Third Annual Leveraged Finance Conference PR Newswire LAVAL, Quebec, May 3, 2018 LAVAL, Quebec , May 3, 2018 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) ("Valeant") today announced that Paul S. Herendeen , executive vice president, Finance, and chief financial officer, is scheduled to participate at the Goldman Sachs Third Annual Leveraged Finance Conference in Rancho Palos Verdes, Calif. on Thursday, May 10, 2018 at 2:10...